These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 23231932)

  • 41. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.
    Kim H; Lim HY
    J Korean Med Sci; 2011 Dec; 26(12):1563-8. PubMed ID: 22147992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
    Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Siegelin MD; Raskett CM; Gilbert CA; Ross AH; Altieri DC
    Neurosci Lett; 2010 Jul; 478(3):165-70. PubMed ID: 20470863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
    Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
    Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells.
    Munagala R; Kausar H; Munjal C; Gupta RC
    Carcinogenesis; 2011 Nov; 32(11):1697-705. PubMed ID: 21859835
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
    Pasqualetti G; Ricciardi S; Mey V; Del Tacca M; Danesi R
    Lung Cancer; 2011 Nov; 74(2):197-205. PubMed ID: 21529991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
    Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
    Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel HSP90 modulator with selective activity against thyroid cancers in vitro.
    Samadi A; Loo P; Mukerji R; O'Donnell G; Tong X; Timmermann BN; Cohen MS
    Surgery; 2009 Dec; 146(6):1196-207. PubMed ID: 19958949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
    Deng L; Ren Z; Jia Q; Wu W; Shen H; Wang Y
    BMC Cancer; 2013 Jul; 13():363. PubMed ID: 23895220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways.
    Zhang S; Doudican NA; Quay E; Orlow SJ
    Anticancer Res; 2011 Oct; 31(10):3259-65. PubMed ID: 21965734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
    Zhang Z; Zhou X; Shen H; Wang D; Wang Y
    BMC Med; 2009 Aug; 7():41. PubMed ID: 19698189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    Jane EP; Premkumar DR; Pollack IF
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
    Matsuse M; Mitsutake N; Tanimura S; Ogi T; Nishihara E; Hirokawa M; Fuziwara CS; Saenko VA; Suzuki K; Miyauchi A; Yamashita S
    Int J Cancer; 2013 Feb; 132(3):738-43. PubMed ID: 22752848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 5'-AMP-Activated Protein Kinase Regulates Papillary (TPC-1 and BCPAP) Thyroid Cancer Cell Survival, Migration, Invasion, and Epithelial-to-Mesenchymal Transition.
    Cazarin JM; Coelho RG; Hecht F; Andrade BM; Carvalho DP
    Thyroid; 2016 Jul; 26(7):933-42. PubMed ID: 27121619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib.
    Ruan ZP; Xu R; Lv Y; Tian T; Wang WJ; Guo H; Nan KJ
    Oncol Res; 2012; 20(2-3):113-21. PubMed ID: 23193917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
    Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
    Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.